Immunomodulatory Effects of Mesenchymal Stromal Cells Revisited in the Context of Inflammatory Cardiomyopathy
Key result
Mesenchymal stromal cells show promise in inflammatory cardiomyopathy by modulating immunity and promoting tissue repair.
Population
Patients with inflammatory cardiomyopathy (myocarditis) and experimental models of viral myocarditis
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support mesenchymal stromal cell therapy in inflammatory cardiomyopathy; leaves open efficacy and safety pending randomized trials.
Structured PICO
P
Population
Patients with inflammatory cardiomyopathy (myocarditis) and experimental models of viral myocarditis
I
Intervention
Mesenchymal stromal cells (MSCs) and cardiac-derived cells (CardAPs)
Mesenchymal stromal cells possess remarkable immunoregulatory properties that may offer a novel therapeutic strategy for inflammatory cardiomyopathy by modulating both innate and adaptive immune responses.
Limitations
- Further understanding of the mechanisms underlying the interplay between immune cells and MSCs is required.
- The consequence of the MSC-mediated suppressive effect on NK function strongly depends on the stage of myocarditis.
- Further investigation is required on the effects of TLR activation on MSCs.
Cite This Study
Miteva et al. (2013) conducted a review in Inflammatory Cardiomyopathy (Myocarditis). Mesenchymal Stromal Cells (MSCs) was evaluated. Mesenchymal stromal cells offer a promising therapeutic strategy for inflammatory cardiomyopathy due to their ability to modulate both innate and adaptive immune responses and support tissue regeneration.